Detailed Information on Publication Record
2004
Prolaction levels in risperidone treatment of first - episode schizophrenia
ČEŠKOVÁ, Eva, Radovan PŘIKRYL, Tomáš KAŠPÁREK and Marta ONDRUŠOVÁBasic information
Original name
Prolaction levels in risperidone treatment of first - episode schizophrenia
Name in Czech
Hladiny prolaktinu u pacientů s první atakou schizofrenie léčených risperidonem
Authors
ČEŠKOVÁ, Eva (203 Czech Republic, guarantor), Radovan PŘIKRYL (203 Czech Republic), Tomáš KAŠPÁREK (203 Czech Republic) and Marta ONDRUŠOVÁ (203 Czech Republic)
Edition
International Journal of Psychiatry in Clinical Practice, Paris, Cambridge University Press, Paris, 2004, 1461-1457
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30000 3. Medical and Health Sciences
Country of publisher
France
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 4.128
RIV identification code
RIV/00216224:14110/04:00025498
Organization unit
Faculty of Medicine
UT WoS
000220242100006
Keywords in English
first-episode schizophrenia; risperidone; treatment response; prolactin; correlation
Změněno: 19/6/2009 15:14, prof. MUDr. Eva Češková, CSc.
V originále
Risperidone in an average dose lower than 4 mg significantly improved both positive and negative symptoms. Co-operating responders undergoing maintanance therapy showed a mild trend towards further long-term improvement. At the end of acute treatment the average elevation of PRL levels almost doubled the baseline value. There was a trend among responders to return to their initial values during long-term therapy. Three-quarters of the subject had hyperprolactinaemia at the end of acute treatment(44 days),and after 1 year about one-quarter had hyperprolactinaemia. No significant correlation between PRL change and PANSS score change was found.
In Czech
Článek pojednává o studii, která mapuje vliv léčby risperidonem u pacientů s první epizodou schizofrenie na hladinu prolaktinu v krvi